The Future of Cholesterol Lowering Therapy: Now?

A short post-today, with important implications:

  • Big news this week from the American College of Cardiology conference! The results of the FOURIER trial were released on-line in the New England Journal of Medicine. In this landmark trial, Evolocumab, a PCSK9 inhibitor already demonstrated to be highly effective at reducing LDL cholesterol levels and atheroma volume (GLAGOV-reference below), was found to be  associated with improved cardiovascular outcomes.
  • Though important questions remain, the demonstrated clinical efficacy represents an important and potentially landmark step forward in the management of patients with high cholesterol.
  • Click to view the study results and accompanying editorial.

Further Reading:

Nicholls SJ, Puri R, Anderson T, et al. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial. JAMA 2016;316:2373-84. 


Leave a Reply